A phase III trial of carboplatin and paclitaxel plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab (nsc #704865, ind #7921) followed by placebo, versus carboplatin and paclitaxel plus concurrent and extended bevacizumab, in women newly diagnosed, previously untreated, stage III or IV, epithelial ovarian, primary peritoneal or fallopian tube cancer nci-supplied agent(s): bevacizumab/ placebo
Principal Investigator
Robert Burger, MD
Status
Terminated
Disease Site
Gynecologic [GY]
Ovarian
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if the addition of 5 concurrent cycles of bevacizumab to 6 cycles of standard therapy (carboplatin and paclitaxel) [Arm II] increases the duration of progression-free survival (PFS) when compared to 6 cycles of standard therapy alone [Arm I] in women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian, peritoneal primary or fallopian tube cancer.
Patient Population
Women with newly diagnosed stage III (with any gross residual disease) and stage IV, epithelial ovarian, peritoneal primary or fallopian tube cancer.
Target Accrual
1800
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.